Global Preventive Vaccines Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 353787
出版日期 內容資訊 英文 149 Pages
商品交期: 2-3個工作天內
預防疫苗的全球市場:疫苗的種類,疾病的徵兆,各地理的成長率,趨勢及預測(2018年∼2023年) Global Preventive Vaccines Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 149 Pages




第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品及服務的威脅
    • 產業內的競爭

第6章 成長要素,阻礙因素,機會,課題分析(DROC)

  • 成長要素
    • 感染疾病流行的擴大
    • 疫苗開發的創新技術
    • 來自政府及國際組織的資金籌措的增加
    • 預防保健的認識高漲
  • 阻礙因素
    • 副作用的風險
    • 莫大的設備投資
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 疫苗的各類型
    • 活病毒疫苗/弱毒化疫苗
    • 不活化疫苗
    • 次單元疫苗
    • 類毒素疫苗
    • 共軛疫苗
    • 重組載體疫苗
    • DNA疫苗
  • 各疾病的徵兆
    • 肺炎球菌疫苗
    • 脊髓灰質炎病毒
    • 肝炎
    • 流感
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Astrazeneca
  • Emergent Biosolutions
  • GeoVax
  • GlaxoSmithKline PLC
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi 等

第10章 市場未來展望


Product Code: 49110

Market Overview

The global preventive vaccines market is currently recording a CAGR of 6.18%. The preventive vaccines market has attained maturity in some of the disease segments, like polio, while for some diseases, it is yet to establish itself in the market. In spite of these differences in each segment, the market is continuously experiencing growth, due to the varying degrees of increase of the demand for vaccination for separate diseases over time. The growth of the global preventive vaccines market is due to the increasing prevalence of infectious diseases, innovative technology in vaccine development, increased funding from government and international organizations, and increasing awareness on preventive care.

Infectious diseases are considered to be the world's greatest killers that pose some of the most significant health and security threats faced by the global community. Various infectious diseases are among the world's leading causes of death. Scientists from every country are currently performing research, sharing information, building laboratory capacity in underdeveloped countries, and creating global surveillance networks in order to prevent and control their spread through preventive vaccinations. However, healthcare costs are rising astronomically and the trends are leaning toward prevention. The cost of vaccination has gone from a single digit to even triple digits few times over the past two decades, thus creating serious dilemmas for doctors and their patients, as well as straining public health budgets.

Scope of the Report

As per the scope of this report, a preventative vaccine is administered to a person who is free of the targeted infection, in order to support the body's immune system against future infections. These vaccines consist of attenuated or killed microbes, or microbial DNA. When administered, the immune system triggers a response that produces antibodies.

Key Market Trends

Live/Attenuated Vaccines Segment is Expected to Exhibit Fastest Growth Rate over the Forecast Period

Live/attenuated vaccines contain weakened versions of living microbes, making them ineffective to cause diseases. These vaccines produce a similar, yet weakened reaction, compared to that of natural infections. The immune system generates strong cellular and antibody responses that often confer lifelong immunity, with only one or two doses. The live/attenuated vaccines need to be refrigerated to stay potent. In addition, if the vaccine needs to be shipped overseas and stored by healthcare workers, in developing countries that lack widespread refrigeration, a live vaccine may not be the best choice. Live/attenuated vaccines for certain viruses are relatively easy to create. Vaccines against measles, mumps, and chickenpox, among others, are designed using this method. Pertaining to the ease of manufacturing, and the ability to generate strong immune responses to the market for live/attenuated vaccines, a steady growth rate is expected during the forecast period.

North America Captured the Largest Market Share and is Expected to Retain its Dominance

North America holds the largest share in the market, with the United States being the largest contributor to its revenue. In the United States, the Centers for Disease Control and Prevention's (CDC) Advisory Committee for Immunization Practices (ACIP) routinely publishes recommendations for adult and childhood vaccination. The United States has one of the leading healthcare systems in the world and the vaccination coverage, in terms of vaccine inclusion, is at par with the WHO guidelines. Thus, the preventive vaccine market in the region is expected to show moderate growth over the forecast period.

Competitive Landscape

Some of the key players in the market are AstraZeneca PLC, Emergent BioSolutions Inc., Daiichi Sankyo Co. Ltd, GlaxoSmithKline PLC, and Johnson & Johnson, among others. These companies are also focusing on innovations, and are spending majorly in R&D in order to lead the global preventive vaccines market, thereby increasing competition among them.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Infectious Diseases
    • 4.2.2 Innovative Technology in Vaccine Development
    • 4.2.3 Increased Funding from Government and International Organizations
    • 4.2.4 Growing Awareness about Preventive Care
  • 4.3 Market Restraints
    • 4.3.1 Risk of Adverse Effects
    • 4.3.2 Huge Capital Expenditures
  • 4.4 Industry Attractiveness Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Vaccine Type
    • 5.1.1 Live/Attenuated Vaccines
    • 5.1.2 Inactivated Vaccines
    • 5.1.3 Subunit Vaccines
    • 5.1.4 Toxoid Vaccines
    • 5.1.5 Conjugate Vaccines
    • 5.1.6 Recombinant Vector Vaccines
    • 5.1.7 DNA Vaccines
  • 5.2 By Disease Type
    • 5.2.1 Pneumococcal
    • 5.2.2 Poliovirus
    • 5.2.3 Hepatitis
    • 5.2.4 Influenza
    • 5.2.5 Measles, Mumps, and Rubella (MMR)
    • 5.2.6 Varicella
    • 5.2.7 Human Papilloma Virus
    • 5.2.8 Other Disease Types
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • United Kingdom
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca PLC
    • 6.1.2 Emergent BioSolutions Inc.
    • 6.1.3 Daiichi Sankyo Co. Ltd
    • 6.1.4 GlaxoSmithKline PLC
    • 6.1.5 Johnson & Johnson
    • 6.1.6 Merck & Co.
    • 6.1.7 Novavax Inc.
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Sanofi SA
    • 6.1.10 Takeda Pharmaceutical Co. Ltd